Category: 637-58-1

Winefordner, J. D. published the artcileThe use of rigid ethanolic solutions for the phosphorimetric investigation of organic compounds of pharmacological interest, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Analytica Chimica Acta (1964), 31(3), 239-45, database is CAplus.

cf. CA 59 13102h; 60, 8605e. The phosphorescence excitation (mμ) and emission maximum (mμ), lifetime (sec.) and limit of detection (γ/ml.) of EtOH solutions at 77°K. of phenobarbital (I), Mebaral, Rutonal, atropine, benzocaine, procaine-HCl, p-aminobenzoic acid, butacaine sulfate, Cyclaine-HCl, Metycaine-HCl, PhCO₂H, cocaine-HCl, quinidine sulfate, quinine-HCl, lidocaine, caffeine, ephedrine, phenylephrinc-HCl, Tronothane-HCl, cinchophen, physostigmine sulfate, and chlortetracycline, are, resp., 240, 380, 1.8, 0.1; 240,380, 2.2, 0.01; 240, 380, 2.5, 0.02; 240,380, 2.1, 0.1; 310, 430, 5.3, 0.007; 310, 430, 3.5, 0.01; 310, 430, 3.2, 0.004; 310, 430, 5.7, 0.05; 240, 400, 2.4, 0.006; 240, 400, 2.7, 0.006; 240, 400, 2.3, 0.005; 240, 400, 2.7, 0.01; 340, 500, 1.3, 0.05; 340, 500, 1.3, 0.04; 265, 400, 1.1, 1.2; 285, 440, 2.0, 0.2; 225, 390, 3.6, 0.2; 290,390, 2.4, 0.01; 300, 410, 1.2, 0.02; 350, 520, 0.8, 0.02; 315, 420, 3.6, 0.03; 280, 410, 2.7, 0.05

Analytica Chimica Acta published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C19H17N3O, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Leonardi, G. published the artcileInteraction between pharmaceuticals and sodium poly(ethylenesulfonate), Category: ethers-buliding-blocks, the publication is Journal of Pharmaceutical Sciences (1966), 55(5), 526-8, database is CAplus.

The interaction of several drugs, mainly local anesthetics, with Na poly(ethylenesulfonate) was studied by means of membrane equilibrium dialysis measurements. Data on equilibrium constants of the association between the drugs considered, as hydrochlorides, and the polyelectrolyte are reported.

Journal of Pharmaceutical Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Category: ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Gohil, Vishal M. published the artcileNutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis, Related Products of ethers-buliding-blocks, the publication is Nature Biotechnology (2010), 28(3), 249-255, database is CAplus and MEDLINE.

Most cells have the inherent capacity to shift their reliance on glycolysis relative to oxidative metabolism, and studies in model systems have shown that targeting such shifts may be useful in treating or preventing a variety of diseases ranging from cancer to ischemic injury. However, we currently have a limited number of mechanistically distinct classes of drugs that alter the relative activities of these two pathways. We screen for such compounds by scoring the ability of >3500 small mols. to selectively impair growth and viability of human fibroblasts in media containing either galactose or glucose as the sole sugar source. We identify several clin. used drugs never linked to energy metabolism, including the antiemetic meclizine, which attenuates mitochondrial respiration through a mechanism distinct from that of canonical inhibitors. We further show that meclizine pretreatment confers cardioprotection and neuroprotection against ischemia-reperfusion injury in murine models. Nutrient-sensitized screening may provide a useful framework for understanding gene function and drug action within the context of energy metabolism

Nature Biotechnology published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Schmidt, A. C. published the artcileCrystal polymorphism of local anesthetic drugs. Part I: Pramocaine base in comparison with pramocaine hydrochloride, Application In Synthesis of 637-58-1, the publication is Journal of Thermal Analysis and Calorimetry (2003), 73(2), 397-408, database is CAplus.

Crystal polymorphs of pramocaine hydrochloride (PRCNC) and pramocaine (PRCN) free base were produced and characterized by means of thermomicroscopy, differential scanning calorimetry (DSC), FTIR- and FT-Raman-spectroscopy as well as x-ray-powder diffractometry. The relative thermodn. stabilities of all forms were determined and are represented in semi-schematic energy/temperature diagrams. PRCN, which is a viscous liquid at room temperature and insoluble in water, was found to exist in two different crystal forms with the m.ps. 23.5° (mod. I°) and 12.5° (mod. II). The water-soluble PRCNC crystallizes in three different crystal modifications. Mod. II° is the thermodynamically stable form at room temperature and is present in com. products. This form is obtained by crystallization from solvents and transforms on heating at about 95° into the high temperature form mod. I which melts at 171.0°. Both compounds show conformational polymorphism with forms of low kinetic stability.

Journal of Thermal Analysis and Calorimetry published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Application In Synthesis of 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Tuesley, Sidney P. published the artcileDevelopment and evaluation of a sampling device for the analysis of pharmaceutical aerosols, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Journal of Pharmaceutical Sciences (1968), 57(3), 488-93, database is CAplus and MEDLINE.

Various devices and techniques were studied in an attempt to obtain suitable samples of material from aerosol products. Generally accepted sampling procedures cannot be used since the aerosol product contains propellants that are extremely volatile. Several of these methods were investigated and used as the basis for assaying various aerosol products. A sampling device was developed and evaluated. The sampling device was designed in a manner that made available a sample of aerosol product that could then be assayed directly in the chamber. Openings were fitted with specially designed valves that allow for transfer of the contents without loss of volatile propellant or active ingredients. Various samples of aerosol products containing local anesthetics, steroids, and amines, were assayed by this method and gave acceptable results. In all cases, the amount of active ingredient contained in each product could be accurately determined The device makes possible a technique applicable to the anal. of most pharmaceutical aerosols. This method, which can be carried out with ease in a relatively short period of time, produced accurate results when used in the manner described.

Journal of Pharmaceutical Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C19H14Cl2, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Park, Sei-Kyoung published the artcileInhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs, HPLC of Formula: 637-58-1, the publication is Microbial Cell (2016), 3(2), 53-64, database is CAplus and MEDLINE.

The formation of small Aβ42 oligomers has been implicated as a toxic species in Alzheimer disease (AD). In strong support of this hypothesis we found that overexpression of Yap1802, the yeast ortholog of the human AD risk factor, phosphatidylinositol binding clathrin assembly protein (PICALM), reduced oligomerization of Aβ42 fused to a reporter in yeast. Thus we used the Aβ42-reporter system to identify drugs that could be developed into therapies that prevent or arrest AD. From a screen of 1,200 FDA approved drugs and drug-like small compounds we identified 7 drugs that reduce Aβ42 oligomerization in yeast: 3 antipsychotics (bromperidol, haloperidol and azaperone), 2 anesthetics (pramoxine HCl and dyclonine HCl), tamoxifen citrate, and minocycline HCl. Also, all 7 drugs caused Aβ42 to be less toxic to PC12 cells and to relieve toxicity of another yeast AD model in which Aβ42 aggregates targeted to the secretory pathway are toxic. Our results identify drugs that inhibit Aβ42 oligomers from forming in yeast. It remains to be determined if these drugs inhibit Aβ42 oligomerization in mammals and could be developed as a therapeutic treatment for AD.

Microbial Cell published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, HPLC of Formula: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Grujic-Vasic, J. published the artcileThin-layer chromatographic separation and colorimetric determination of some local anesthetics and tropane alkaloids, HPLC of Formula: 637-58-1, the publication is Glasnik Hemicara i Tehnologa Bosne i Hercegovine (1970), 41-6, database is CAplus.

Tropane alkaloids and local anesthetics can be separated by thin-layer chromatog. on cellulose powder D impregnated with a borate/phosphate buffer at pH 6.6, using n-butanol saturated with H2O. Quant. determination is carried out by the method of Decker, et al. (1965).

Glasnik Hemicara i Tehnologa Bosne i Hercegovine published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, HPLC of Formula: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Nikolic, Kosta published the artcileElectro-analytical determination of some compounds from a group of synthetic local anesthetics, SDS of cas: 637-58-1, the publication is Arhiv za Farmaciju (1977), 27(1), 37-43, database is CAplus.

Amylocaine-HCl [532-59-2], butanilcaine-HCl [6027-28-7], dibucaine-HCl [61-12-1], falicaine [1155-49-3], cornecaine [3686-68-8], pramoxine-HCL [637-58-1], and tetracaine-HCl [136-47-0] in DMSO were determined by conductometric titration with KOH. The standard deviations were 0.2, 0.2, 0.1, 0.3, 0.3, 0.1 and 0.2, reps.

Arhiv za Farmaciju published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, SDS of cas: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Young, Trudye A. published the artcileA pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients, COA of Formula: C17H28ClNO3, the publication is Journal of Dermatological Treatment (2009), 20(2), 76-81, database is CAplus and MEDLINE.

Objective: The objective of this study was to evaluate the efficacy of a com. available anti-itch lotion containing 1% pramoxine hydrochloride vs. control lotion in the treatment of uremic pruritus in adult hemodialysis patients. Methods: This was a randomized, double-blind, controlled comparative trial set in a community hemodialysis center. The study population comprised 28 individuals (mean age 53.5) with moderate to severe uremic pruritus who had been receiving hemodialysis for at least 3 mo. All participants were recruited from one community hemodialysis center. Topical anti-itch lotion containing 1% pramoxine was applied twice daily to all affected areas of pruritus for 4 wk. The main outcome measure was a reduction in itch intensity. Secondary outcomes included increases in the investigator’s global assessment and improvement in skin hydration. Results: There was a 61% decrease in itch intensity in the treatment group, whereas a 12% reduction in itch intensity was observed in the control group. The rate of decline in itching was also greater in the treatment arm vs. the control arm. No significant differences were displayed in other studied disease-related variables. Conclusion: Our study shows that individuals using pramoxine 1% lotion experienced a reduction in pruritus to a greater degree than those using the control lotion. This safe, convenient and effective topical lotion may potentially benefit the large number of patients affected by pruritus associated with end-stage renal disease.

Journal of Dermatological Treatment published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C6H17NO3Si, COA of Formula: C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Keiser, Jennifer published the artcileEvaluation of an FDA approved library against laboratory models of human intestinal nematode infections, Related Products of ethers-buliding-blocks, the publication is Parasites & Vectors (2016), 376/1-376/10, database is CAplus and MEDLINE.

Background: Treatment options for infections with soil-transmitted helminths (STH) – Ascaris lumbricoides, Trichuris trichiura and the two hookworm species, Ancylostoma duodenale and Necator americanus – are limited despite their considerable global health burden. The aim of the present study was to test the activity of an openly available FDA library against laboratory models of human intestinal nematode infections. Methods: All 1,600 drugs were first screened against Ancylostoma ceylanicum third-stage larvae (L3). Active compounds were scrutinized and toxic compounds, drugs indicated solely for topical use, and already well-studied anthelmintics were excluded. The remaining hit compounds were tested in parallel against Trichuris muris first-stage larvae (L1), Heligmosomoides polygyrus third-stage larvae (L3), and adult stages of the three species in vitro. In vivo studies were performed in the H. polygyrus and T. muris mice models. Results: Fifty-four of the 1,600 compounds tested revealed an activity of > 60% against A. ceylanicum L3 (hit rate of 3.4%), following incubation at 200μM for 72 h. Twelve compounds progressed into further screens. Adult A. ceylanicum were the least affected (1/12 compounds active at 50μM), while eight of the 12 test compounds revealed activity against T. muris L1 (100μM) and adults (50μM), and H. polygyrus L3 (200μM). Trichlorfon was the only compound active against all stages of A. ceylanicum, H. polygyrus and T. muris. In addition, trichlorfon achieved high worm burden reductions of 80.1 and 98.9%, following a single oral dose of 200 mg/kg in the T. muris and H. polygyrus mouse model, resp. Conclusion: Drug screening on the larval stages of intestinal parasitic nematodes is feasible using small libraries and important given the empty drug discovery and development pipeline for STH infections. Differences and commonalities in drug activities across the different STH species and stages were confirmed. Hits identified might serve as a starting point for drug discovery for STH.

Parasites & Vectors published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem